understanding temporal trends in hiv prevalence, incidence and arv dr valerie delpech head of hiv...
TRANSCRIPT
Understanding temporal trends in HIV prevalence, incidence and ARV
Dr Valerie DelpechHead of HIV surveillancePublic Health England
How do we measure TasP at the population level?
2
Challenges of Test and Treat
• Efficacy versus effectiveness• Individual versus public health benefit
• Feasibility and acceptability
• Ethics
• Resistance and toxicity
• Role of primary HIV infection in transmission• MSM versus heterosexual epidemics
• Role of undiagnosed HIV in transmission
• Linkage to care and access to ART
3 3
• ?Elimination or ?decrease in incidence /new HIV
infections
• ?Elimination or ?reduction in AIDS deaths
• ?Impact on STIs
How do we monitor our successes and failures?
• Hard measures – ‘surveillance’ data in key populations
• new diagnosis, AIDS and non AIDS deaths
• late diagnosis, linkage and retention in care, testing and treatment uptake, viral suppression – ‘continuum of care
• STI rates, behavioural data
• Estimates
• incidence, undiagnosed infections
• Should NOT be used as ‘substitute’ for surveillance
What is successful Treatment as Prevention?
HIV Prevention Technologies Shown to Be Effective in Reducing HIV Incidence in Randomized Clinical Trials
5
Granich RM et al, Lancet 2009; 373: 48–57
HIV incidence
6
2000 2020 2040
British Columbia, Canada: Montaner et al (2010)
7
8
Among approximately 77,600 persons living with diagnosed HIV infection in the UK
• 97% are linked to care after diagnosis within 3 months
• 95% are retained in care annually
• 92% of persons in need are on treatment (85% of all persons in care)
• 95% of persons on treatment achieve VL<200 copies/ml
9 Mortality and causes of death among women living with HIV in the UK in the era of HAART
Annual new HIV and AIDS diagnoses and deaths: UK, 1981-2012
First test for HIV
ART available
New HIV diagnoses in the UK by exposure category: 2003 - 2012
10
2003 2004 2005 2006 2007 2008 2009 2010 2011 20120
1000
2000
3000
4000
5000
6000
Sex between men (adjusted) Sex between men (observed)Heterosexual contact (adjusted) Heterosexual contact (observed)Injecting drug use (adjusted) Other (adjusted)Not reported
Year of first HIV diagnosis in the UK
Nu
mb
ers
of
new
HIV
dia
gn
ose
s
Uptake and HIV tests among MSM attending STI clinics, UK
CD 4 back-calculation method of annual HIV incidence in MSM: England & Wales 2001-2010
Birrell P.J. Gill O.N., Delpech V.C et al (2013). HIV incidence in men who have sex with men in England andWales 2001–10: a nationwide population study. The LancetID-D-12-0107 - S1473-3099(12)70341-9
HIV in the United Kingdom: 2013
Back-calculation estimate of HIV incidence and prevalence of undiagnosed infection among
MSM: UK, 2003-2012
SOPHIDMPES
Treatment cascade of adults living with HIV: United Kingdom, 2012
14 Treatment cascade of adults living with HIV: United Kingdom, 2011
HIV infected (n=98,400) HIV diagnosed Retained in care On treatment Undectable VL0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%100%
79%73%
69%62%
UK Continuum of care ‘cascade’
DATA SOURCES• Estimates of undiagnosed infections using Multi Parameter
Evidence Synthesis Model • Routine HIV surveillance data • UA programmes in key pops• Natsal – nationally representative sexual health survey• Behavioural data in key pops
• ‘In care’ data consists of linked comprehensive national data • new diagnoses • CD4 and VL laboratory data• Persons in HIV clinics - annual updates
15 Presentation title - edit in Header and Footer
London
Less than 11-2>2
Prevalence of diagnosed HIV infection by region of residence among population aged 15-59 years: United Kingdom, 2011
16
People living with HIV by diagnostic and treatment status, and number with detectable viral load, UK, 2006-2012
2008 2009 2010 2011 20120
20000
40000
60000
80000
100000
120000 Diagnosed and treated Diagnosed and untreated
Undiagnosed Number with VL>50 copies
HIV epidemic in the United Kingdom
19801982
19841986
19881990
19921994
19961998
20002002
20042006
20082010
0
5000
10000
15000
20000
25000
30000
35000
40000
45000
50000
55000
60000
65000
70000
75000
New HIV diagnoses
No.
First Year of HIV care is crucial
late diagnoseslink to carehigh uptake of ARThigh 1 yr mortality in late Dx
20 HIV in the United Kingdom: 2013
Late HIV diagnosis: Proportion* of adults diagnosed with a CD4 count <350 cells ,UK, 2012
HIV and STI Department, Health Protection Agency - Colindale
HIV and AIDS Reporting System
¹Prompt diagnosis: CD4 count ≥350 cells/mm³ within 91 days of diagnosis²Late diagnosis: CD4 count <350 cells/mm³ within three months of diagnosis³Percentage of patients known to have died within a year of diagnosis.
Prompt1 and late² HIV diagnosis in MSM with associated short-term mortality³: United Kingdom, 2002 - 2011
0
200
400
600
800
1000
1200
1400
1600
1800
-2%
0%
2%
4%
6%
8%
10%Diagnosed PromptlyNumber Diagnosed
Short-term mortality
Num
ber
Dia
gnosed (
bars
)
Short
-term
mort
ality
rate
(line)
0
200
400
600
800
1000
1200
1400
1600
0%
2%
4%
6%
8%
10%Diagnosed Late
Number Diagnosed
Short-term mortality
Num
ber
Dia
gnosed (
bars
)
Short
-term
mort
ality
rate
(line)
Exploration of the CD4 Data Warehouse – South Africa
Simbarashe Takuva, Adrian PunenAliison Brown, Valerie Delpech
Centre for HIV and STIs, National Institute for Communicable Diseases,
NHLS, Johannesburg.
22
PLHIV in South Africa: Spectrum estimatePersons in HIV Care using CD4 as marker
23
CD4 Count Distribution, SA2004-2012
24Source: CDW, 2013
HIV clinical dashboard
Individual based clinical outcome data at the local level
HIV clinical dashboard: England
Outcome name Measure England 2012Late diagnosis % newly diagnosed patients with a CD4 count
<350 cells/mm3 at diagnosis47%28% (CD4<200)
Linkage to care % newly diagnosed patients with a CD4 count test done within 28 days of diagnosis
89%(97% in 3 months)
Retention in care after diagnosis
% newly diagnosed patients retained in HIV care one year after diagnosis
95%
Retention in care of all patients
% of all patients retained in HIV care in the following year
85%
Immunological response
% of all patients seen for HIV care with a CD4 count > 350
85%(95%>200)
ART coverage % of patients in care on ARV 89 %Viral load suppression
% of patients with an undetectable viral load (VL<50 copies/ml) one year after initiating treatment
88%(95%<200)
Poster number: WEPE175
HIV Dashboard: Quality of care for newly-diagnosed by trust
27 Poster number: WEPE175
• 135 trusts in England• 5,808 newly-diagnosed
adults in 2012• 4,820 linked to HARS
cohort record
1 10 19 28 37 46 55 64 73 82 91 1001091181270%
20%
40%
60%
80%
100%
Figure 3. Retention in care among newly diagnosed adults
England mean (85%)
1 10 19 28 37 46 55 64 73 82 91 1001091181270%
20%
40%
60%
80%
100%
Figure 1. Late HIV diagnosis
CD4<350 (late) CD4<200 (very late)England mean (47%)
1 10 19 28 37 46 55 64 73 82 91 100 109 1180%
10%20%30%40%50%60%70%80%90%
100%
Figure 2. Linkage to care after diagnosis
CD4 in 91 days CD4 in 28 daysEngland mean (89%)
Quality of care dashboard for all adults in care by Trust
28Poster number: WEPE175
1 10 19 28 37 46 55 64 73 82 91 1001091180%
20%
40%
60%
80%
100%
Figure 6. Viral load suppression 1 year after start of treatment
VL<200 VL<50 England mean (88%)
1 11 21 31 41 51 61 71 81 91 1011111211310%
20%
40%
60%
80%
100%
Figure 7. Immunological response after one year of care
CD4>200 CD4>350 England mean (85%)
1 11 21 31 41 51 61 71 81 91 1011111211310%
20%
40%
60%
80%
100%
Figure 4. Anual retention in among all adults
England mean (95%)
1 11 21 31 41 51 61 71 81 91 1011111211310%
20%
40%
60%
80%
100%
Figure 5. Antiretrovieral therapy coverage among adults with
CD4<350England mean (89%)
Conclusions and Public health relevance
• Successes (and failures) of public health policies including TasP can be measured using basic routine surveillance data for key risk groups and over time
• Accurate and comprehensive (representative) data and clear consistent methodologies are key for tracking progress
• HIV surveillance data should be linked to vital statistics death data
• CD4 data are extensively used to track the epidemic – • late diagnosis, link to care, retention in care, back-calculation estimates, as well
as evaluation of treatment guidelines, estimates of incidence and undiagnosed
• VL – provide insight into success of treatment programs and ongoing transmission
• Other markers are also important – STI and behavioural data
• Clinical dashboards at the local level in key populations provide accountability and can drive improvements
29 Presentation title - edit in Header and Footer
NO ONE SHOULD DIE OF AIDS IN 2014
NO ONE
ANYWHERE 30
We gratefully acknowledge
all the persons living with HIV as well as
clinicians, health advisors, nurses,
microbiologists, public health practitioners,
data managers and other colleagues who
contribute to
the surveillance of HIV and STIs in the UK.
Thank-you